Published in Gastroenterology on July 14, 2011
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol (2013) 1.07
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Hepatocellular carcinoma--resection or transplant? Nat Rev Gastroenterol Hepatol (2012) 0.92
Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol (2013) 0.90
Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol (2012) 0.90
Clinical utility of entecavir for chronic hepatitis B in Chinese patients. Drug Des Devel Ther (2013) 0.88
Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl (2013) 0.83
Outcome of various treatments for posttransplant hepatitis B virus recurrence. World J Surg (2013) 0.81
Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One (2014) 0.81
Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol (2014) 0.80
Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol (2013) 0.80
Rescue Living-donor Liver Transplantation for Liver Failure Following Hepatectomy for Hepatocellular Carcinoma. Liver Cancer (2013) 0.80
Prophylaxis against Recurrence in Liver Transplantation Patients with Hepatitis B Virus: What is New? J Clin Transl Hepatol (2014) 0.79
Safe and cost-effective control of post-transplantation recurrence of hepatitis B. Hepatol Res (2014) 0.79
Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation. Gastroenterol Hepatol (N Y) (2014) 0.79
Initiation of liver transplantation in bangladesh: report on the first two successful cases. J Health Popul Nutr (2014) 0.79
Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation. PLoS One (2012) 0.78
Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation. Springerplus (2014) 0.78
Management of chronic hepatitis B in severe liver disease. World J Gastroenterol (2014) 0.78
One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. Can J Gastroenterol Hepatol (2013) 0.77
Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol (2015) 0.77
Hepatitis B immunoglobulin prophylaxis after liver transplantation: experience in a tertiary transplant centre. J Clin Exp Hepatol (2014) 0.76
Hepatitis B and Hepatitis C Reactivation in the Biologic Era. J Clin Transl Hepatol (2014) 0.76
Hepatitis B immune globulin in liver transplantation prophylaxis: an update. Hepat Mon (2012) 0.76
Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. Int J Mol Sci (2015) 0.76
Management of chronic hepatitis B before and after liver transplantation. World J Hepatol (2015) 0.76
Management of hepatitis B virus infection after liver transplantation. World J Gastroenterol (2015) 0.75
Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol (2015) 0.75
Combined prophylaxis might still be better than monoprophylaxis with entecavir following liver transplantation for hepatitis B. Gastroenterology (2011) 0.75
Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation. World J Hepatol (2015) 0.75
Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Transplantation (2015) 0.75
Prophylactic managements of hepatitis B viral infection in liver transplantation. World J Gastroenterol (2016) 0.75
Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J Clin Transl Hepatol (2016) 0.75
Update on entecavir in the management of severe forms of Hepatitis B. Hepat Med (2012) 0.75
Prophylaxis of hepatitis B infection in solid organ transplant recipients. Therap Adv Gastroenterol (2013) 0.75
Prevention of hepatitis B virus infection: from the past to the future. Eur J Clin Microbiol Infect Dis (2015) 0.75
The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients. J Gastroenterol (2016) 0.75
Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation. Dig Dis Sci (2015) 0.75
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
Viral hepatitis C. Lancet (2003) 5.81
Viral hepatitis B. Lancet (2003) 4.86
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol (2008) 4.55
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg (2013) 3.11
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology (2002) 2.90
HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology (2008) 2.84
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology (2003) 2.73
Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology (2013) 2.66
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med (2007) 2.52
Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg (2015) 2.36
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective. J Nucl Med (2013) 2.29
Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol (2008) 2.24
High frequency of chimerism in transplanted livers. Hepatology (2003) 2.15
Pure Laparoscopic Hepatectomy Versus Open Hepatectomy for Hepatocellular Carcinoma in 110 Patients With Liver Cirrhosis: A Propensity Analysis at a Single Center. Ann Surg (2016) 2.14
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis (2013) 2.11
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg (2011) 2.05
Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts. Transplantation (2013) 2.00
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med (2007) 1.92
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology (2004) 1.83
Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol (2013) 1.81
SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology (2004) 1.81
High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann Surg (2011) 1.79
Abdominal drainage after hepatic resection is contraindicated in patients with chronic liver diseases. Ann Surg (2004) 1.79
A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer (2002) 1.77
Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther (2007) 1.76
Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76
Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol (2011) 1.73
Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol (2013) 1.73
Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol (2011) 1.73
The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol (2009) 1.72
Does the addition of endoscopic sphincterotomy to stent insertion improve drainage of the bile duct in acute suppurative cholangitis? Gastrointest Endosc (2003) 1.64
Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. Transplantation (2003) 1.61
Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology (2010) 1.61
A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology (2012) 1.60
Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int (2011) 1.60
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Choledochal cysts in adults. Arch Surg (2002) 1.59
Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol (2004) 1.55
Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol (2011) 1.53
Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg (2013) 1.51
Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transpl (2012) 1.49
CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology (2012) 1.48
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg (2008) 1.44
Chronic hepatitis B--new goals, new treatment. N Engl J Med (2008) 1.42
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology (2009) 1.40
Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol (2006) 1.40
Low-volume deceased donor liver transplantation alongside a strong living donor liver transplantation service. World J Surg (2014) 1.40
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol (2008) 1.36
A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology (2004) 1.34
Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology (2007) 1.32
Safety and necessity of including the middle hepatic vein in the right lobe graft in adult-to-adult live donor liver transplantation. Ann Surg (2003) 1.32
Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother (2011) 1.32
Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology (2006) 1.31
Biliary reconstruction and complications of right lobe live donor liver transplantation. Ann Surg (2002) 1.31
Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg (2007) 1.30
Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol (2009) 1.29
Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Carcinogenesis (2008) 1.28
Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol (2008) 1.28
Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology (2004) 1.28
Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis (2002) 1.23